Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across ...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
New York, New York-- (Newsfile Corp. - March 17, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is ...
Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types
Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested ...
BioSpace9d
Pliant Pops Poison Pill as Concentra Threat Looms
Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...
Fierce Biotech9d
Pliant, Acelyrin resort to ‘poison pills’ as threat of Concentra buyout looms
With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up ...
AlphaQuest LLC Reduces Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX)
AlphaQuest LLC lowered its position in Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) by 73.9% during the 4th quarter, ...
American Association of Individual Investors7d
Why Pliant Therapeutics, Inc.’s (PLRX) Stock Is Up 10.39%
Pliant Therapeutics, Inc.’s PLRX share price has surged by 10.39%, which has investors questioning if this is right time to sell.
The Manila Times10d
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement
SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that ...
HC Wainwright Reaffirms “Neutral” Rating for Pliant Therapeutics (NASDAQ:PLRX)
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “neutral” rating restated by HC Wainwright in a research ...
BioPharma Dive9d
Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’
President Trump’s nominee to run the FDA secured the Senate HELP Committee’s backing. Elsewhere, Sutro cut jobs and a cell ...
Investing7d
Pliant reports promising results for tumor treatment drug
SOUTH SAN FRANCISCO - Pliant Therapeutics, Inc. (NASDAQ: PLRX), a biopharmaceutical company currently valued at $94.3 million, announced interim results from a Phase 1 clinical trial of PLN-101095 ...